However, our BC cohort showed slightly more CDH1 and ERBB2 mutations in ILC, and more GATA3 mutations in non-lobular BC than reported in previous studies (Supplementary Fig. 3 and Supplementary Table 3). This evidence concerns the gene ERBB2 and breast cancer.